Lexaria Bioscience (LEXX) Intangibles (2015 - 2026)
Lexaria Bioscience's (LEXX) quarterly Intangibles came in at $20193.0 in Q1 2026, down 96.01% year-on-year from $506180.0 in Q1 2025, and up 296.02% quarter-over-quarter from $5099.0 in Q4 2025.
Lexaria Bioscience (LEXX) Intangibles (2015 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Intangibles across 12 years of filings, most recently posting $20193.0 for Q1 2026.
- Intangibles for Q1 2026 came in at $20193.0, down 96.01% year-over-year; the trailing twelve-month figure through Feb 2026 was $20193.0 (down 96.01% YoY), and the FY2025 annual result was $307818.0, down 40.42% from the prior year.
- Intangibles came in at $20193.0 for Q1 2026 at Lexaria Bioscience, up from $5099.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $549122.0 in Q2 2023 to a low of $5099.0 in Q4 2025.
- The 5-year median for Intangibles is $488462.0 (2022), against an average of $358795.1.
- Across the five-year window, Intangibles surged 574.54% in 2023 and sank 98.99% in 2025, its largest moves.
- Lexaria Bioscience's Intangibles stood at $500549.0 in 2022, then dropped by 1.23% to $494377.0 in 2023, then grew by 2.22% to $505373.0 in 2024, then tumbled by 98.99% to $5099.0 in 2025, then jumped by 296.02% to $20193.0 in 2026.
- The last three Intangibles figures came in at $20193.0 (Q1 2026), $5099.0 (Q4 2025), and $307818.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 7.73 Mn |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | 20,193.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 20,193.00 |
| Nov 30, 2025 | 5,099.00 |
| Aug 31, 2025 | 307,818.00 |
| May 31, 2025 | 516,420.00 |
| Feb 28, 2025 | 506,180.00 |
| Nov 30, 2024 | 505,373.00 |
| Aug 31, 2024 | 516,676.00 |
| May 31, 2024 | 119,018.00 |
| Feb 29, 2024 | 97,016.00 |
| Nov 30, 2023 | 494,377.00 |
| Aug 31, 2023 | 462,625.00 |
| May 31, 2023 | 549,122.00 |
| Feb 28, 2023 | 517,730.00 |
| Nov 30, 2022 | 500,549.00 |
| Aug 31, 2022 | 488,462.00 |
| May 31, 2022 | 81,407.00 |
| Feb 28, 2022 | 411,452.00 |
| Nov 30, 2021 | 378,746.00 |
| Aug 31, 2021 | 364,623.00 |
| May 31, 2021 | 366,340.00 |